CN: 32-1845/R
ISSN: 2095-6975
Cite this paper:
LIN Mei-Yu, YUAN Zhong-Lan, HU Dan-Dan, HU Gan-Hai, ZHANG Ri-Li, ZHONG Hua, YAN Lan, JIANG Yuan-Ying, SU Juan, WANG Yan. Effect of loureirin A against Candida albicans biofilms[J]. Chinese Journal of Natural Medicines, 2019, 17(8): 616-623

Effect of loureirin A against Candida albicans biofilms

LIN Mei-Yu1, YUAN Zhong-Lan1, HU Dan-Dan1, HU Gan-Hai1,2, ZHANG Ri-Li1, ZHONG Hua1, YAN Lan1, JIANG Yuan-Ying1, SU Juan1, WANG Yan1
1 School of Pharmacy, Naval Military Medical University, Shanghai 200433, China;
2 Department of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350000, China
Loureirin A is a major active component of Draconis sanguis, a traditional Chinese medicine. This work aimed to investigate the activity of loureirin A against Candida albicans biofilms. 2, 3-Bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) reduction assay and scanning electron microscopy were used to investigate the anti-biofilm effect. Minimal inhibitory concentration testing and time-kill curve assay were used to evaluate fungicidal activity. Cell surface hydrophobicity (CSH) assay and hyphal formation experiment were respectively carried out to investigate adhesion and morphological transition, two virulence traits of C. albicans. Real-time RT-PCR was used to investigate gene expression. Galleria mellonella-C. albicans and Caenorhabditis elegans-C. albicans infection models were used to evaluate the in-vivo antifungal effect. Human umbilical vein endothelial cells and C. elegans nematodes were used to evaluate the toxicity of loureirin A. Our data indicated that loureirin A had a significant effect on inhibiting C. albicans biofilms, decreasing CSH, and suppressing hyphal formation. Consistently, loureirin A down-regulated the expression of some adhesion-related genes and hypha/biofilm-related genes. Moreover, loureirin A prolonged the survival of Galleria mellonella and Caenorhabditis elegans in C. albicans infection models and exhibited low toxicity. Collectively, loureirin A inhibits fungal biofilms, and this effect may be associated with the suppression of pathogenic traits, adhesion and hyphal formation.
Key words:    Candida albicans    Loureirin A    Anti-biofilm    Morphological transition   
Received: 2019-05-24   Revised:
PDF (2775 KB) Free
Print this page
Email this article to others
Articles by LIN Mei-Yu
Articles by YUAN Zhong-Lan
Articles by HU Dan-Dan
Articles by HU Gan-Hai
Articles by ZHANG Ri-Li
Articles by ZHONG Hua
Articles by YAN Lan
Articles by JIANG Yuan-Ying
Articles by SU Juan
Articles by WANG Yan
[1] Fan JY, Yi T, Sze-To CM, et al. A Systematic review of the botanical, phytochemical and pharmacological profile of Dracaena cochinchinensis, a plant source of the ethnomedicine "Dragon's Blood"[J]. Molecules, 2014, 19(7):10650-10669.
[2] Cui JL, Wang CL, Guo SX, et al. Stimulation of dragon's blood accumulation in Dracaena cambodiana via fungal inoculation[J]. Fitoterapia, 2013, 87:31-36.
[3] Choy CS, Hu CM, Chiu WT, et al. Suppression of lipopolysaccharide-induced of inducible nitric oxide synthase and cyclooxygenase-2 by Sanguis Draconis, a dragon's blood resin, in RAW 264.7 cells[J]. J Ethnopharmacol, 2008, 115(3):455-462.
[4] Zhu H, Wu Q, Xu M. Effects of total Astragalus extract on anti-thrombus[J]. Chin J Clin Pharmacol Ther, 2005, 10:917-920.
[5] Cai RX, Liu JJ. The preliminary report of the antimicrobial effect of Guangxi dragon's blood[J]. J Guilin Med Coll, 1990, 3(1):16-19.
[6] Alangaden GJ. Nosocomial fungal infections:epidemiology, infection control, and prevention[J]. Infect Dis Clin North Am, 2011, 25(1):201-225.
[7] Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System[J]. J Infect Dis, 1993, 167(5):1247-1251.
[8] Crnich CJ, Maki DG. The promise of novel technology for the prevention of intravascular device-related bloodstream infection. I. Pathogenesis and short-term devices[J]. Clin Infect Dis, 2002, 34(9):1232-1242.
[9] Fesharaki SH, Aghili SR, Shokohi T, et al. Catheter-related candidemia and identification of causative Candida species in patients with cardiovascular disorder[J]. Curr Med Mycol, 2018, 4(2):7-13.
[10] Lohse MB, Gulati M, Johnson AD, et al. Development and regulation of single-and multi-species Candida albicans biofilms[J]. Nat Rev Microbiol, 2018, 16(1):19-31.
[11] Maki DG, Tambyah PA. Engineering out the risk for infection with urinary catheters[J]. Emerg Infect Dis, 2001, 7(2):342-347.
[12] Nguyen MH, Peacock JE, Tanner DC, et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study[J]. Arch Intern Med, 1995, 155(22):2429-2435.
[13] Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis[J]. Clin Infect Dis, 2004, 38(2):161-189.
[14] Chandra J, Kuhn DM, Mukherjee PK, et al. Biofilm formation by the fungal pathogen Candida albicans:development, architecture, and drug resistance[J]. J Bacteriol, 2001, 183(18):5385-5394.
[15] Seneviratne CJ, Jin L, Samaranayake LP. Biofilm lifestyle of Candida:a mini review[J]. Oral Dis, 2008, 14(7):582-590.
[16] Li DD, Wang Y, Dai BD, et al. ECM17-dependent methionine/cysteine biosynthesis contributes to biofilm formation in Candida albicans[J]. Fungal Genet Biol, 2013, 51:50-59.
[17] Sherry L, Rajendran R, Lappin DF, et al. Biofilms formed by Candida albicans bloodstream isolates display phenotypic and transcriptional heterogeneity that are associated with resistance and pathogenicity[J]. BMC Microbiol, 2014, 14:182.
[18] Chandra J, Mukherjee PK, Leidich SD, et al. Antifungal resistance of candidal biofilms formed on denture acrylic in vitro[J]. J Dent Res, 2001, 80(3):903-908.
[19] Ramage G, Vandewalle K, Wickes BL, et al. Characteristics of biofilm formation by Candida albicans[J]. Rev Iberoam Micol, 2001, 18(4):163-170.
[20] Vila TV, Ishida K, de Souza W, et al. Effect of alkylphospholipids on Candida albicans biofilm formation and maturation[J]. J Antimicrob Chemother, 2013, 68(1):113-125.
[21] Li DD, Zhao LX, Mylonakis E, et al. In vitro and in vivo activities of pterostilbene against Candida albicans biofilms[J]. Antimicrob Agents Chemother, 2014, 58(4):2344-2355.
[22] Prakash P, Solanki A, Joshi KR. A simple synthetic liquid medium for development of yeast and mycelial form of pathogenic species of Candida[J]. Indian J Pathol Microbiol, 1997, 40(1):55-58.
[23] Hwang SB, Choi JG, Wei S, et al. In vivo screening platform for shiga toxin-producing Escherichia coli (STEC) using Caenorhabditis elegans as a model[J]. PLoS One, 2018, 13(2):e0193277.
[24] Zhao LX, Li DD, Hu DD, et al. Effect of tetrandrine against Candida albicans biofilms[J]. PLoS One, 2013, 8(11):e79671.
[25] Dhale RP, Ghorpade MV, Dharmadhikari CA. Comparison of various methods used to detect biofilm production of Candida species[J]. J Clin Diag Res, 2014, 8(11):18-20.
[26] Li DD, Deng L, Hu GH, et al. Using Galleria mellonella-Candida albicans infection model to evaluate antifungal agents[J]. Biol Pharm Bull, 2013, 36(9):1482-1487.
[27] Fuchs BB, O'Brien E, Khoury JB, et al. Methods for using Galleria mellonella as a model host to study fungal pathogenesis[J]. Virulence, 2010, 1(6):475-482.
[28] Pukkila-Worley R, Peleg AY, Tampakakis E, et al. Candida albicans hyphal formation and virulence assessed using a Caenorhabditis elegans infection model[J]. Eukaryot Cell, 2009, 8:1750-1758.
[29] Breger J, Fuchs BB, Aperis G, et al. Antifungal chemical compounds identified using a C. elegans pathogenicity assay[J]. PLoS Pathog, 2007, 3(2):e18.
[30] Samaranayake YH, Wu PC, Samaranayake LP, et al. Relationship between the cell surface hydrophobicity and adherence of Candida krusei and Candida albicans to epithelial and denture acrylic surfaces[J]. APMIS, 1995, 103(10):707-713.
[31] Luo G, Samaranayake LP. Candida glabrata, an emerging fungal pathogen, exhibits superior relative cell surface hydrophobicity and adhesion to denture acrylic surfaces compared with Candida albicans[J]. APMIS, 2002, 110(9):601-610.
[32] Maidan MM, De Rop L, Serneels J, et al. The G protein-coupled receptor Gpr1 and the Galpha protein Gpa2 act through the cAMP-protein kinase A pathway to induce morphogenesis in Candida albicans[J]. Mol Biol Cell, 2005, 16(4):1971-1986.
[33] Li Y, Xiao W, Qin J, et al. Simultaneous determination of five active components in resina draconis and its extract by HPLC[J]. China J Chin Mater Med, 2012, 37(7):929-933.
[34] Kempf M, Cottin J, Licznar P, et al. Disruption of the GPI protein-encoding gene IFF4 of Candida albicans results in decreased adherence and virulence[J]. Mycopathologia, 2009, 168(2):73-77.
[35] Li F, Svarovsky MJ, Karlsson AJ, et al. Eap1p, an adhesin that mediates Candida albicans biofilm formation in vitro and in vivo[J]. Eukaryotic Cell, 2007, 6(6):931-939.
[36] Sudbery PE. Growth of Candida albicans hyphae[J]. Nat Rev Microbiol, 2011, 9(10):737-748.
[37] Hogan DA, Sundstrom P. The Ras/cAMP/PKA signaling pathway and virulence in Candida albicans[J]. Future Microbiol, 2009, 4(10):1263-1270.
[38] Liu H, Köhler J, Fink GR. Suppression of hyphal formation in Candida albicans by mutation of a STE12 homolog[J]. Science, 1994, 266(5191):1723-1726.
[39] Zeidler U, Lettner T, Lassnig C, et al. UME6 is a crucial downstream target of other transcriptional regulators of true hyphal development in Candida albicans[J]. Fems Yeast Research, 2009, 9(1):126-142.
[40] Pérez A, Pedrós B, Murgui A, et al. Biofilm formation by Candida albicans mutants for genes coding fungal proteins exhibiting the eight-cysteine-containing CFEM domain[J]. Fems Yeast Research. 2006, 6(7):1074-1084.
[41] Borghi E, Romagnoli S, Fuchs BB, et al. Correlation between Candida albicans biofilm formation and invasion of the invertebrate host Galleria mellonella[J]. Future Microbiol, 2014, 9(2):163-173.
[42] Tan X, Fuchs BB, Wang Y, et al. The role of Candida albicans SPT20 in filamentation, biofilm formation and pathogenesis[J]. PLoS One, 2014, 9(4):e94468.
[43] Pompilio A, Piccolomini R, Picciani C, et al. Factors associated with adherence to and biofilm formation on polystyrene by Stenotrophomonas maltophilia:the role of cell surface hydrophobicity and motility[J]. Fems Microbiol Lett, 2008, 287(1):41-47.
[44] Leberer E, Harcus D, Broadbent ID, et al. Signal transduction through homologs of the Ste20p and Ste7p protein kinases can trigger hyphal formation in the pathogenic fungus Candida albicans[J]. Proc Natl Acad Sci USA, 1996, 93(23):13217-13222.
[45] Lo HJ, Kohler JR, DiDomenico B, et al. Nonfilamentous C. albicans mutants are avirulent[J]. Cell, 1997, 90(5):939-949.
[46] Saville SP, Lazzell AL, Monteagudo C, et al. Engineered control of cell morphology in vivo reveals distinct roles for yeast and filamentous forms of Candida albicans during infection[J]. Eukaryot Cell, 2003, 2(5):1053-1060.